Loading
Life sciences · Review
Nutrients · November 5, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Review.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Metabolic syndrome (MetS) encompasses a spectrum of disease pathologies that include dyslipidaemia, insulin resistance, hypertension, obesity, and inflammation. The rising prevalence of MetS and the associated morbidity and mortality represent a growing burden on global healthcare. MetS’s hallmarks are readily quantified and can be used to assess development and progression of the syndrome. Nutraceuticals, bioactive compounds derived from natural sources such as plants, fruits, cultures and grains, have a potential role in protection against cardiometabolic diseases. Relevant actions of nutraceuticals include their antioxidant, probiotic, anti-inflammatory, insulin-sensitising, lipid-modifying, anti-adiposity, and endothelial protective functions. This review explores the evidence for common nutrient deficiencies in metabolic syndrome alongside their role in preventing and modifying the complex elements that characterise this prevalent disease cluster.